SGC Press Releases

Monday 19th December 2016

http://www.nature.com/nsmb/journal/vaop/ncurrent/full/nsmb.3343.html

Oxford, UK, December 19, 2016, Scientists from the Structural Genomics Consortium (SGC) and Oxford University report a three-dimensional view of the Polycystin-2 (PC2), a protein that causes autosomal dominant polycystic kidney disease (ADPKD) when mutated, in an article published today in Nature Structural and Molecular Biology.

Friday 7th October 2016

Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award.

Monday 12th September 2016

Target-enabling packages provide a crucial link between human genetics and disease biology to accelerate drug discovery in cancer and malaria

Wednesday 13th April 2016

We are delighted to announce a groundbreaking partnership between The Brain Tumour Charity and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and initiating clinical trials within unusually short timeframes.

Monday 29th February 2016

DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, today announced its partnership with the Structural Genomics Consortium (SGC), a public-private organization established in 2003, to develop selective and potent chemical probes for the unexplored human kinome and to promote open sharing of these probes with the scientific community.

Thursday 4th February 2016

Pan-Canadian Team of Researchers Will Receive CA$11.7 Million in Funding from Stand Up To Cancer Canada, Genome Canada, Canadian Institutes of Health Research, Cancer Stem Cell Consortium, and Ontario Institute for Cancer Research

Wednesday 16th December 2015

University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation. The new funding brings the total investment from the Bill & Melinda Gates Foundation to nearly US $12 million since 2012.

Friday 4th December 2015

Takeda Pharmaceutical Company Limited (Takeda) today announced it has renewed its partnership with the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to patients faster.

Thursday 3rd September 2015

Through a novel open source approach the molecule has been made freely available to the cancer research community to help discover new therapeutic strategies for cancer patients sooner.

Monday 25th May 2015

Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) join forces with small and medium-sized enterprise (SMEs) as well as universities and hospitals in an Innovative Medicines Initiative (IMI) supported public private partnership, ULTRA-DD. In this project, we aim to define and validate new drug targets in inflammatory and auto-immune diseases by testing high quality chemical probes and antibodies in patient-cell derived assays to facilitate a greater understanding of disease pathology.

Pages

Subscribe to SGC Press Releases
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03